Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) (NCT06274801)
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH)
🩺 Plain-English Summary (8th-Grade Level)
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
Who can join: Review the eligibility criteria below.
Location: Valley Advanced Lung Diseases Institute — Fresno, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (120 Sites)
Showing the first 25 of 120 sites.
- Valley Advanced Lung Diseases Institute — Fresno, California
- Department of Veterans Affairs Greater Los Angeles Healthcare System — Los Angeles, California
- UC Davis Health Medical Center — Sacramento, California
- Stanford Healthcare — Stanford, California
- University of Florida Health — Gainesville, Florida
- Mayo Clinic Jacksonville — Jacksonville, Florida
- Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead — Atlanta, Georgia
- The Emory Clinic — Atlanta, Georgia
- Northside Hospital - Atlanta — Atlanta, Georgia
- UI Health Hospital — Chicago, Illinois
- University of Kansas Medical Center — Kansas City, Kansas
- Norton Pulmonary Specialists — Louisville, Kentucky
- University of Michigan — Ann Arbor, Michigan
- Washington University School of Medicine — St Louis, Missouri
- University of Nebraska Medical Center — Omaha, Nebraska
- University of New Mexico Health Sciences Center — Albuquerque, New Mexico
- NYU Langone Health — New York, New York
- University of Rochester Medical Center — Rochester, New York
- UNC Hospitals — Chapel Hill, North Carolina
- University of Cincinnati Medical Center — Cincinnati, Ohio
- INTEGRIS Cardiovascular Physicians — Oklahoma City, Oklahoma
- The Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
- Temple Heart and Vascular Institute (Outpatient Clinic) — Philadelphia, Pennsylvania
- UPMC Presbyterian Hospital — Pittsburgh, Pennsylvania
- Medical University of South Carolina - Nexus Research Center — Charleston, South Carolina
📞 Contact the Study Coordinator
Phone: (866) 668-4083
Email: ClinicalTrials@gossamerbio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Arterial Hypertension
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION) — Aurora, Colorado
- A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension — Phoenix, Arizona
- Pulmonary Vascular Disease Phenomics Program PVDOMICS — Tucson, Arizona
- An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) — Jacksonville, Florida
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension — Aurora, Colorado
- ADAPT - A Patient Registry of the Real-world Use of Orenitram® — Fresno, California
Explore by condition: All Pulmonary Arterial Hypertension clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.